Video

Tardive dyskinesia: Screening and management

Author and Disclosure Information

Sanjay Gupta, MD, discusses the importance of using the Abnormal Involuntary Movement Scale (AIMS) to screen for tardive dyskinesia, and treating the disorder with vesicular monoamine transporter-2 (VMAT-2) inhibitors.


 

Recommended Reading

Aripiprazole, brexpiprazole, and cariprazine: Not all the same
MDedge Psychiatry
Aripiprazole, brexpiprazole, and cariprazine
MDedge Psychiatry
Early trauma exposure tied to telomere shortening in men with schizophrenia
MDedge Psychiatry
Consanguineous parentage raises risk of mood disorders, psychoses in offspring
MDedge Psychiatry
MDedge Psychcast: Interview with Dr. Henry Nasrallah
MDedge Psychiatry
Targeting obesity could slow brain aging in psychosis
MDedge Psychiatry
Real-world data so far support pimavanserin trial results
MDedge Psychiatry
Substance use linked to conversion to schizophrenia
MDedge Psychiatry
MDedge Daily News: Lupus is quietly killing young women
MDedge Psychiatry
Schizophrenia: Psychiatrists ‘can do much more’ for patients
MDedge Psychiatry